The proposal could affect telehealth services that rely on outside facilities to produce the knockoff drugs in bulk.
The US FDA has proposed an end to most types of compounding of semaglutide, tirzepatide, and liraglutide. The agency said in a statement it has determined there is no longer a clinical need for ...
In Canada, health regulators took one step to fill that gap by approving a generic version of semaglutide, which is the ...
Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding. ・The 503B Bulk List features ...
Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably heard ...
Does Compounded Semaglutide Work for Weight Loss? Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But it’s important to understand ...
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...
Weight loss with Ozempic or Wegovy can be frustrating when it comes to the availability and price of the popular drugs. That’s driving some people to compounding pharmacies for copycat treatments, but ...
I first met Jane (not her real name, of course) on a Friday afternoon in our clinic. She was referred for further evaluation of her chest pain, which, in the context of her family history of ...
Add Yahoo as a preferred source to see more of our stories on Google. Compounded GLP-1 drugs aren't FDA-approved and may carry unknown safety risks. Experts warn of inconsistent quality, dosing and ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...